In order to produce a new lead for anti-tubercular drug a series of novel 2-trichloromethyl quinazoline derivatives bearing substituted secondary amine group at the 4 th position were designed, synthesized and evaluated for their in vitro anti-tubercular activity against bacterial strain of M. tuberculosis H37Rv ATCC (American Type Culture Collection) by Alamar Blue assay method (MABA). The targeted molecules (4a-j) were synthesized from 4-chloro-2-(trichloromethyl) quinazoline and substituted secondary amine in dichloromethane using catalytic amount of KI, under reflux for 15-18 h. All the targeted compounds are new chemical entities and obtained in satisfactory yields and the structure of the synthesized compounds are in agreement with spectral data. Compound 4a and 4f exhibited potent anti-tubercular activity against bacterial strain of M. tuberculosis H37Rv, with MIC value 6.25 µG.
Introduction
Tuberculosis is one of the oldest and most pervasive diseases in history 1, 2 . According to alarming data from the World Health Organization (WHO), TB has spread to every corner of the globe. It is estimated that between 2002 and 2020, approximately 1000 million people will be newly infected, over 150 million people will develop diseases and 36 million will die due to TB if proper control measures are not established 3 . The directly observed treatment, short course (DOTS) strategy, constitutes the cornerstone of the current protocol for control of TB. However, the three key drugs, isoniazide, pyrazinamide and rifampicin, used in the regimen are potentially hepatotoxic and may lead to drug associated hepatitis 4 . Despite the undoubted success of DOTS strategy, the emergence of multi drug resistant strains, recurrently isolated from patient's sputum, darken the future. Furthermore, one of the main cases for the prevalence of TB is synergy with HIV epidemic, where 31% of new TB cases are attributable to HIV co-infection 5 .
RESEARCH ARTICLE
Many compounds are in clinical trials, it is astonishing that with this background, there have been no new drugs registered to treat TB in the last 45 yrs. This reflects the inherent difficulties in discovery and clinical testing of new agents and the lack of pharmaceutical industry research in this area 6 . It was reported that quinazoline molecule were identified as a possible pharmacophores for anti-tubercular activity [7] [8] [9] [10] . In the quest for biologically potent antitubercular agents, we have designed, synthesized and screened some 2-trichloromethyl-4-substituted quinazoline derivatives to mimic those reported as potential anti-tubercular agents [7] [8] [9] [10] .
Experimental
All the reagents and chemicals were procured from Sigma-Aldrich Company and used without further purification. Melting points were determined by using an open capillary tube method and are uncorrected. IR spectra (V max in cm -1 ) were recorded on a Shimadzu FT-IR 8300 Spectrophotometer using KBr pellets technique.
1 HNMR Spectra were recorded using Bruker WM-400 spectrophotometer using CDCl 3 as the solvent and tetramethylsilane (TMS) as the internal reference (Chemical Shifts in δ, ppm). The purity of newly synthesized compounds was checked by TLC using silica gel G60 (Merck, Germany) plates in n-hexaneethyl acetate (9:1) solvent system and spots were visualized under UV light. 
2-Acetamidobenzoic acid (1)

2-Methylquinazolin-4(3H)-one (2)
2-Acetamidobenzoic acid (1) 
4-Chloro-2-(trichloromethyl) quinazoline (3)
2-Methyl quinazolin-4(3H)-one (2) (1.6 g, 10.0 mmol), phosphorous pentachloride (10.41 g, 50 mmol) and phosphorous oxychloride (20 mL) were heated under reflux for 6 h at 115-118 o C. Excess of phosphorous oxychloride was removed by distillation under reduced pressure. The residue was extracted three times with ethyl acetate. The combined organic phase was washed with sodium bicarbonate solution (5.0%), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The crude product thus obtained was purified by column chromatography (60/120) using n-hexane-ethyl acetate (9:1) mixture as eluent to give compound 3 in yield 47%; m. 
4-Substituted-2-(trichloromethyl)quinazolines (4a-j)
4-Chloro-2-(trichloromethyl) quinazoline (1.4 g, 5 mmol), appropriate secondary amine (10 mmol) were dissolve in 15 mL of dichloromethane and catalytic amount of KI was added.
The mixture was refluxed for 15-18 h. After completion of reaction (TLC monitored), the solvent was evaporated and the residue was extracted (10 mL x 3) with hot petroleum ether. Combined extracts upon cooling resulted solid separation, which was recrystallized by petroleum ether to afford color solids. (Yields: 55-85%, Table 1 ). 
4-(4-Methylpiperazin-1-yl)-2-(trichloromethyl)quinazoline (4a)
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N, N-Diethyl-2-(trichloromethyl)quinazolin-4-amine (4g)
4-(1H-imidazol-1-yl)-2-(trichloromethyl)quinazoline (4h)
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4-(Piperazin-1-yl)-2-(trichloromethyl)quinazoline (4i)
4-(1,4-Diazepan-1-yl)-2-(trichloromethyl)quinazoline (4j)
In vitro evaluation of anti-tubercular activity
The anti-tubercular activity of the newly synthesized compounds was evaluated by Micro plate Alamar Blue assay method (MABA) 11 on bacterial strain M. tuberculosis H37Rv ATCC (American Type Culture Collection), inoculums was grown on 100 mL of Middle brook 7H9 broth (Difco, Detroit Mich.) supplemented with 0.2% (v/v) glycerol, 10% (v/v) OADC (Oleic acid, albumin, dextrose, catalase, Difco) and 0.5% (v/v) Tween 80. The complete medium referred to as 7H9GC-T80. The Anti-TB susceptibility testing was performed in black, clear bottomed, 96-well microplates in order to minimize background fluorescence. Initial drug dilution was prepared in dimethyl sulfoxide and subsequent two fold dilutions were performed in 0.1 mL of 7H12 media in the micro plates. The H 37 Rv was diluted in 7H9 media to reach approximately 2x105 cfu/mL and 0.1 mL was added to wells. Wells containing compounds only were used to detect auto fluorescence of the compounds and were incubated at 37 o C. At day 7 of incubation, 20 µL of Alamar blue solution and 12.5 mL of 20% Tween 80 were added to all the wells and the plates were re-incubated at 37 o C for 24 h. A blue color in the well was interpreted as no bacterial growth, and pink color was scored as growth. The MIC was defined as lowest drug concentration which prevented the color change from blue to pink. The pyrazinamide and streptomycin were employed as standard drugs for the comparison of antitubercular activity and the results were tabulated in the Table 2 . 
S-sensitive, R-resistant
Results and Discussion
The synthetic strategies adopted for the preparation of targeted compound is depicted in Scheme 1. The targeted compounds (4a-j) were synthesized by reacting 4-chloro-2-(trichloromethyl) quinazoline (3) with various substituted secondary amine in dichloromethane medium refluxing for 15-18 h under the catalysis of KI. The precursor N-acetylated anthranilic acid (1) was synthesized by refluxing anthranilic acid with acetic anhydride, which was further cyclized to 2-methyl quinazoline (2) by heating with formamide at 160 o C. The 2-methyl quinazoline (2) was subjected for trichlorination of activated methyl group in α-position of the sp 2 nitrogen atom in quinazoline by using phosphorous pentachloride as a powerful ionic chlorinating agent and phosphorous oxychloride as a solvent. The structure of targeted compounds was established by IR, 1 HNMR and Mass spectral analysis, all the targeted compounds were obtained in satisfactory yields and the structures of synthesized compounds are in agreement with spectral data.
In vitro anti-tubercular activity
Ten analogs namely 4a, 4b, 4c, 4d, 4e, 4f, 4g , 4h, 4i and 4j were evaluated for in-vitro Antitubercular activity by Alamar Blue assay method (MABA) on bacterial strain M. tuberculosis H37Rv. The results are presented in Table 2 as MIC Value. The obtained data revealed that, all the tested compounds exhibited variable degree of sensitivity profiles towards bacterial strain of M. tuberculosis H37Rv. Among the tested compounds 4a and 4f
In particular, compounds 4a and 4f proved to be the most active members in this study with a special effectiveness against the bacterial strain M. tuberculosis H37Rv having MIC value 6.25 µG. A close examination of the structure of the active compounds showed that the N-methyl piprazine and 4-diethanolamine counterpart at postion-4 of the 2-trilchlorometyl quinazoline skeleton is the most favorable substitution when compared with the other analogues. The differences in the MIC values may be attributed to factors such as substitution on the 4 th position of 2-tichloromethyl quinazoline nucleus, genetic and biochemical background of bacterial strain M. tuberculosis H37Rv ATCC (American Type Culture Collection).
Conclusion
The present paper describe the synthesis of 4-substituted -2-(trichloromethyl) quinazoline derivatives as possible anti-tubercular agents. The investigation of anti-tubercular activity data revealed that the compounds 4a and 4f displayed excellent activity. These lead molecules 4a and 4f could be further utilized for designing newer anti-tubercular agents.
